Billy,
My take on it is that Timmy B. (SEPR pres.) said the magic words in his
quarterly quote:
"In the second quarter, we filed our New Drug Application (NDA)
for nebulized levalbuterol," said Timothy J. Barberich, President
and Chief Executive Officer. "This filing came approximately two
years after the drug entered U.S. human clinical trials, confirming
our ability to develop important ICE s in a short time frame. We
look forward to continued clinical progress in the third and fourth
quarters, as we continue our human studies on compounds such as
norastemizole, (R,R)-formoterol, and (S)-oxybutynin. In addition, we
will continue to conduct studies on levalbuterol."
With no news on Oxybutynin out by now I bet some of the more antsy types
had figured that no news was bad news. The UBS guy had projected an
early June announcement date for the Oxy study. So by Timmy adding it
to his list of stuff that he is looking forward to "continued clinical
progress" it looks like Oxy is still on the table. This drug could be
the biggest of SEPR's lot. It treats adult incontinence better than Ditropan,
without anywhere near the side effects.
Also, they are scheduled to file an NDA for the syrup version of
levalbuterol by the end of the year and folks may have been reminded of
that from his quote. The syrup form of levalbuterol covers only about
half the market as the nebulizer form, but its still big bucks. |
